Study Finds Ruxolitinib Effective, Safe for Children With AD Study Finds Ruxolitinib Effective, Safe for Children With AD

There were no significant safety signals in the younger pediatric population, and ' no treatment-emergent adverse events suggestive of systemic JAK inhibition, ' Dr Lawrence Eichenfield said.MDedge News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news